Hanson wade have taken the decision to cancel this meeting.
Please do accept our apologies for any inconvenience or disappointment this will cause.

Please register your interest here if you would like updates on the meeting or topic.

Delivery of Cell Therapies in Diabetes: Encapsulation and Beyond

Expert Speakers

Kfir Molakandov

Project Director, Diabetes Cell Therapy

Kadimastem

Matthias von Herrath

Vice President & Senior Medical Officer, Global Chief Medical Officer

Novo Nordisk

Albert Hwa

Operations Director, CCTD, Lecturer in Medicine

Harvard Medical School, Joslin Diabetes Centre

William Rust

CEO & President

Seraxis

Kuldeep Singh Neote

VP, External Innovation

Eli Lilly

Preventing alloreactivity of engrafted cells for treatment in diabetes is of utmost importance to ensure efficacy and durability of treatment. Encapsulation methods and the utilization of medical devices allows cells to be able to do this, however, the techniques and technologies are vast and varied during this working group we will aim to tackle the key challenges involved with the delivery of cell therapies in diabetes, discussions include:

  • Oxygenation of cells
  • Permeability of membranes
  • Macro and micro-encapsulation
  • Medical device innovations
  • And more

Join leaders in development as they share key learnings in case studies, have an open and frank panel discussion and become an active participant in the conversation during breakout discussion groups.

Key Topics of Discussion

*All agenda times in EST

9:00 am Introduction & Opening Remarks

9:20 am CASE STUDY: Functional Enrichment for Insulin Producing Cells from hPSCs Large Scale Cultures Using Novel Cell Surface Markers Combination

Synopsis

• Using cell-capture antibody array, novel antibodies to distinguish hPSC-derived islets cell populations
• Enriching for cells using a novel antibody combination and re-aggregation with MACS technology and large-scale cultures
• In vitro and in vivo functional analysis for sorted cells
• Strategy development for reducing required cell mass loaded into an encapsulation device to potentially decrease the device’s physical dimensions

9:40 am CASE STUDY: Defining New Combination Therapies to Intervene in Type 1 Diabetes

  • Matthias von Herrath Vice President & Senior Medical Officer, Global Chief Medical Officer, Novo Nordisk

Synopsis

• The issues of immunity and reoccurrence of autoimmunity and allorecognition
• Strategies using stem cells to overcome allorecognition
• Discussing capsules and implantation

10:00 am CASE STUDY: Extra-Hepatic Sites for Transplanting Insulin-Producing Cells

  • Albert Hwa Operations Director, CCTD, Lecturer in Medicine, Harvard Medical School, Joslin Diabetes Centre

Synopsis

• Engraftment efficiency of stem cell-derived beta cells
• Establishment of beta cell mass and functional response
• Off-target cell populations and safety considerations

10:20 am Virtual Speed Networking

11:00 am CASE STUDY: Functional Enrichment for Insulin Producing Cells from hPSCs Large Scale Cultures Using Novel Cell Surface Markers Combination

Synopsis

• Using cell-capture antibody array, novel antibodies to distinguish hPSC-derived islets cell populations
• Enriching for cells using a novel antibody combination and re-aggregation with MACS technology and
large-scale cultures
• In vitro and in vivo functional analysis for sorted cells
• Strategy development for reducing required cell mass loaded into an encapsulation device to potentially
decrease the device’s physical dimensions

12:00 pm BREAKOUT DISCUSSION GROUPS

Synopsis

• What microstructures provide an immune protective environment to prevent sensitization and rejection?
• What is the optimal pore size in membranes required for encapsulation and how does this effect the
distance molecule have to travel, selectivity and permeability?
• How long will cells survive in an encapsulation device and will the cells have to be replaced periodically?
• What are the various strategies to supply sufficient oxygen to maintain islet function?
• What are the approaches to utilizing scaffolding techniques to overcome patient’s alloimmunity and
autoimmunity?

12:45 pm Feedback Summary & Key Takeaways

1:00 pm End of Working Group A